Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation

NCT03683433 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Acute Bilineal Leukemia
Acute Biphenotypic Leukemia
Chronic Myelomonocytic Leukemia
IDH2 Gene Mutation
Myelodysplastic Syndrome
Recurrent Acute Myeloid Leukemia
Refractory Acute Myeloid Leukemia

Interventions

DRUG: Azacitidine
DRUG: Enasidenib Mesylate

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]